Open Monoclonal Technology, Inc. (OMT), an innovator in transgenic
research for discovery of human therapeutic antibodies, today announced
that Genentech, a member of the Roche Group, and Roche RHHBY will acquire unlimited access to OmniRat®
through the purchase of one of OMT's spinout companies. Following the
acquisition, Genentech and Roche will be able to use the platform to
generate human therapeutic antibodies for any target and indication.
Genentech and Roche also gained the right to further engineer the
antibody platform.
“Genentech is a leader in the discovery and development of innovative
therapeutic antibodies,” said Dr. James Sabry, Senior Vice President and
Global Head of Genentech Partnering. “We believe that OmniRat
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in